Novo Nordisk Faces a Reality Check: Q1 Earnings Loom as Valuation Debate Intensifies

Novo Nordisk faces pivotal Q1 earnings amid a 36% YTD stock drop, competitive pressure from Eli Lilly, and a deep valuation divide as analysts remain split on recovery.

Novo Nordisk enters a pivotal week with its first-quarter earnings due Wednesday, caught between a brutal valuation reset and tentative signs of stabilization. The Danish drugmaker’s shares have clawed back roughly 17 percent from a 52-week low of $35.12, closing April at $42.22 — but the recovery masks deep fractures in investor confidence.

The Lilly Effect Cuts Both Ways

Eli Lilly’s blockbuster quarterly report provided an unexpected tailwind for its Danish rival. Barclays described Lilly’s decision to raise its 2026 revenue guidance by $2 billion as neutral to positive for Novo Nordisk, arguing that it validates continued expansion of the GLP-1 market. Yet Lilly’s surging Mounjaro sales — up 125 percent in the first quarter — also underscore the competitive pressure bearing down on Novo’s Wegovy and Ozempic franchises.

A more nuanced picture emerges from prescription data. Lilly’s newly approved oral pill Foundayo generated roughly 3,700 prescriptions in its second week on the market. By contrast, Novo Nordisk’s oral GLP-1 therapy notched over 18,000 prescriptions in a comparable period — a data point that has temporarily eased fears about Wegovy’s market position.

A Deep Valuation Divide

The stock’s trajectory tells a stark story. Down roughly 36 percent year-to-date, Novo Nordisk now trades at about 12 times earnings — a fraction of Lilly’s 26-times multiple. Morningstar pegs the fair value at just $18, implying the current share price of roughly $40 to $41 carries an 85 percent premium. That assessment underscores just how inflated valuations became during the 2024 GLP-1 euphoria.

Wall Street remains sharply divided. Six analysts maintain buy ratings with an average price target near $58, betting that long-term growth potential outweighs near-term headwinds. But recent downgrades tell a different tale: Citi cut its rating, Bernstein initiated with “underperform,” and the consensus price target has been slashed by more than 21 percent over the past three months. Goldman Sachs holds a $41 target — barely above the current level — while Kepler Capital reiterated “hold” in late April.

The Numbers That Matter

The Q1 report is expected to deliver sobering figures. Analysts forecast an 8 percent year-over-year revenue decline and a 16 percent drop in earnings per share. For the full year, Novo Nordisk itself projects adjusted revenue growth between negative 5 percent and negative 13 percent at constant exchange rates.

Morningstar warns that US prices for semaglutide could fall more than 20 percent in 2026, driven by Medicare Part D negotiations and most-favored-nation clauses. That would hit margins harder and sooner than previously modeled.

Counterweights to the Gloom

Several factors offer support. The FDA recently proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk substance list — a move against compounding pharmacies that sent Novo Nordisk shares up nearly 5 percent. Conversely, Health Canada’s approval of an injectable semaglutide generic has spooked investors, with some analysts viewing it as a potential precedent for other markets.

Novo Nordisk’s partnership with OpenAI, announced in mid-April, aims to integrate artificial intelligence across research, manufacturing, and supply chain operations by the end of 2026. The announcement lifted the stock roughly 2.8 percent, though financial terms were not disclosed.

A $15 billion Danish kroner share buyback program and the expected expansion of Medicare coverage for obesity drugs by mid-2026 provide additional ballast. The dividend yield already stands at roughly 4 percent, and one analyst characterizes the stock as a “get paid to wait” story, with free cash flow yield projected above 6.5 percent in 2027.

What Wednesday Will Reveal

Beyond the headline numbers, investors will scrutinize management’s forward guidance. The key question is whether the full-year outlook holds or requires another downward revision. With the stock’s relative strength index recently touching 23 — deep in oversold territory — and the 30-day gain of roughly 14 percent hinting at stabilization, the Q1 report could determine whether the recovery has legs or proves to be a dead-cat bounce.